I kēia manawa, aia ka COVID-19 i ke kūlana maʻi maʻi a puni ka honua. ʻO ka superposition o nā ʻano like ʻole Delta a me Omicron, e hopena i ka hoʻonui mau ʻana o kā lākou hiki ke hoʻouna. Ma waena o nā nalu hou o COVID-19, i ka hoʻohui ʻana i ka maʻi COVID-19, ʻo ka hoʻomohala ʻana i nā lāʻau lapaʻau COVID-19 waha a me nā ʻano hoʻokolohua wikiwiki, maʻalahi a me nā ʻano hou i lilo i koi hou no ka pale ʻana a me ka mālama ʻana i nā maʻi maʻi. ʻO Viva Biotech Holdings a me XLement, i hoʻokomo ʻia a hoʻokomo ʻia e Viva BioInnovator, ua kūpaʻa i ka hana ʻana i nā lāʻau lapaʻau COVID-19 waha a me ka hoʻāʻo ʻana i ka maʻi virus, e hāʻawi ana i ka hakakā ʻana i ka maʻi maʻi COVID-19.
Ua hōʻailona ʻo Langhua Pharmaceutical i ka ʻaelike me MPP e hana i ka mea kanu o ka COVID-19 antiviral lāʻau molnupiravir.
Ian 2022, ua hoʻolaha ka Medicines Patent Pool (MPP) ua kau inoa ʻo ia i nā ʻaelike me kekahi mau ʻoihana hana maʻamau e like me Zhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), ʻo ia ka lālā o Viva biotech holdings (Viva Biotech (01873.HK)) no. ka hana ʻana i ka lāʻau antiviral COVID-19 waha molnupiravir a hāʻawi i nā ʻāina haʻahaʻa haʻahaʻa a me waena (LMICs) 105 e hoʻomaʻamaʻa i ke komo ʻana o ka honua no ka molnupiravir a kākoʻo i ka pale ʻana a me ka mālama ʻana i nā maʻi maʻi kūloko. ʻElima mau hui e kālele ana i ka hana ʻana i nā mea maka, 13 mau hui e hoʻopuka i nā mea ʻelua a me ka lāʻau lapaʻau i hoʻopau ʻia a ʻo 9 mau hui e hana i ka lāʻau i pau.
ʻO ka Medicines Patent Pool (MPP) he hui olakino lehulehu i kākoʻo ʻia e United Nations e hana ana e hoʻonui i ke komo ʻana i, a hoʻomaʻamaʻa i ka hoʻomohala ʻana i nā lāʻau ola ola no nā ʻāina haʻahaʻa a me waena. ʻO MPP a me MSD, ka inoa kālepa o Merck & Co., Inc Kenilworth NJ USA ua kau inoa i kahi ʻaelike laikini manawaleʻa ma ʻOkakopa 2021. Ma lalo o nā ʻōlelo o ka ʻaelike, MPP, ma o ka laikini i hāʻawi ʻia e MSD, e ʻae ʻia e ʻae hou aku i ka laikini ʻole. sublicences i nā mea hana ("MPP Licence") a hoʻololi i ke kahua hana no ka hoʻolako ʻana i ka molnupiravir i hōʻoia ʻia i ka maikaʻi i nā ʻāina i uhi ʻia e ka Laikini MPP, ma muli o ka mana hoʻoponopono kūloko.
ʻO Molnupiravir (MK-4482 a me EIDD-2801) kahi ʻano noiʻi, hoʻokele waha ʻia o kahi analog ribonucleoside ikaika e pale ai i ka hana hou ʻana o SARS-CoV-2 (ke kumu kumu o COVID-19). ʻO Molnupiravir e hoʻomohala nei ʻo MSD me ka Ridgeback Biotherapeutics, ʻo ia ka lāʻau antiviral waha mua i loaʻa no ka maʻi COVID-19. Ua hōʻike ka ʻikepili mai ka Phase 3 MOVe-OUT i ka mālama mua ʻana me ka molnupiravir i hōʻemi nui i ka pilikia o ka hale maʻi a i ʻole ka make i ka nui o ka pilikia, nā pākeke ʻaʻole i hoʻopaʻa ʻia me COVID-19.
Wahi a MPP, ua hōʻike maikaʻi nā hui i hāʻawi ʻia i ka sublicence i ko lākou hiki ke hoʻokō i nā koi o MPP e pili ana i ka hiki ke hana, ka hoʻokō hoʻoponopono, a me ka hiki ke hoʻokō i nā kūlana honua no nā lāʻau lapaʻau maikaʻi. ʻO ka ʻae i hāʻawi ʻia iā Langhua Pharmaceutical e MPP e hōʻike ana i kahi hōʻoia kiʻekiʻe a me ka hoʻomaopopo ʻana i kāna hana hoʻomohala a me ka hoʻonui ʻana i nā API, hoʻolako i ka hoʻomau, GMP a me ka ʻōnaehana EHS.
Ua hala ka pahu ho'āʻo COVID-19 o Xlement i ka nānā ʻana o ke Kuhina ʻepekema a me ʻenehana o ka Repubalika o Kina me ka lanakila.
Ma Malaki 2nd, 2022, ua loaʻa iā Xlement, kahi ʻoihana biochip NanoSPR kūpaʻa a me nā mea hana biotech i hoʻopuka mua ʻia a incubated e Viva BioInnovator, i loaʻa ka leka hoʻomaopopo o ka hāʻawi ʻana i ka loiloi hana mai ka Ministry of Science and Technology of the People's Republic of China. ʻO kāna papahana "R&D a me Mass Production of NanoSPR COVID-19 Particle Test Kit" kekahi o nā papahana koʻikoʻi o ka papahana "Public Safety Risk Prevention and Control and Emergency Response Technology and Equipment" e lawelawe ana i kahi ʻāpana koʻikoʻi i ke kī COVID-19- noiʻi ʻepekema pili e holo nei ma Kina. Me kona holo kūleʻa i ka nānā ʻana, ua hōʻoia ʻia ʻo Xlement's COVID-19 Test Kit e ka European Union CE no ka hana nui e hiki mai ana a e hoʻohana koke ʻia.
Hoʻohana ʻia ma ka ʻenehana chip NanoSPR kūʻokoʻa, ua hoʻomohala ʻo Xlement i ka pahu hoʻāʻo no nā ʻāpana COVID-19, e ʻae i ka hoʻāʻo ʻana i hoʻokahi ʻanuʻu o nā antigen virus lehulehu no 96 mau laʻana i loko o 15 mau minuke, a ua kokoke ka naʻau i ka hoʻāʻo ʻana i hoʻokahi antigen. Hōʻike kēia ʻano i nā pōmaikaʻi nui i hoʻohālikelike ʻia i nā ʻenehana hoʻāʻo viral nucleic acid: hiki ke hoʻohana ʻia no ka hoʻāʻo ponoʻī ʻana ma ka home, pōkole ia i ka manawa hoʻāʻo nui, no laila, hoʻemi nui i ke kumukūʻai o ka hoʻāʻo ʻana i nā reagents a me ka hana. Me ka hoʻohana hou ʻana i ka ʻenehana NanoSPR i ka hoʻāʻo COVID-19 i hoʻomohala ʻia e Xlement, manaʻo mākou e ʻike i ka maʻalahi o ka maʻi maʻalahi o nā laʻana i manaʻo ʻia a me ka nānā wikiwiki ʻana ma ka pūnaewele ma ka nui.
He aha e lawe ʻia mai kēia ʻatikala:
- Ma Malaki 2nd, 2022, ua loaʻa iā Xlement, kahi ʻoihana biochip NanoSPR a me nā mea hana biotech i hoʻopuka mua ʻia a hoʻokomo ʻia e Viva BioInnovator, i ka leka hoʻomaopopo o ka hāʻawi ʻana i ka loiloi hana mai ka Ministry of Science and Technology of the People's Republic of China.
- Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non-exclusive sublicences to manufacturers (“MPP Licence”) and diversify the manufacturing base for the supply of quality-assured molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.
- Ma waena o nā nalu hou o COVID-19, i ka hoʻohui ʻana i ka maʻi COVID-19, ʻo ka hoʻomohala ʻana i nā lāʻau lapaʻau COVID-19 waha a me nā ʻano hoʻokolohua wikiwiki, maʻalahi a me nā mea hou i lilo i koi hou no ka pale ʻana a me ka mālama ʻana i nā maʻi maʻi.
